Please login to the form below

Not currently logged in
Email:
Password:

Industry veteran Louis Nisbet joins Sygnature board

Brings experience from Roche, Glaxo and SmithKline

Sygnature Louis NisbetSygnature Discovery has appointed Dr Louis Nisbet to its board as a non-executive director.

The UK-based clinical research organisation (CRO) will benefit from Dr Nisbet's extensive experience in the life sciences industry, which includes spells in research at Roche, Glaxo and SmithKline.

Following this period, he became an entrepreneur, helping to found companies such as Xenova, Brax and InTouch with Health.

Dr Nisbet's current roles include serving as venture partner with Kurma Life Sciences Partners and chairman of the science park BioCity in Nottingham, UK.

Sygnature's CEO Dr Simon Hirst commented that Dr Nisbet joins the board at a time of growth for the company, which includes the recent addition of in vitro bioscience to its capabilities and enhancing its computational chemistry and informatics capabilities.

“Louis will provide us with advice and guidance as we continue our expansion and evolution as a business,” said Dr Hirst.

1st October 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics